Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2588318 | 0.98 | OPRM1 (0.40) | OPRM1OPRL1CHRNB2CHRNA4HRH3 | |
| SCHEMBL2587479 | 0.79 | CHRM2 (0.44) | OPRM1OPRL1HRH3SLC6A4SLC6A2 | |
| SCHEMBL2580066 | 0.76 | KDM4E (0.39) | OPRL1CHRNB2CHRNA4SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL2583472 | 0.74 | OPRL1 (0.38) | OPRM1OPRL1CHRNB2CHRNA4SLC6A4 | |
| SCHEMBL2591223 | 0.73 | KCNH2 (0.34) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2590114 | 0.72 | EPHX2 (0.37) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14936525 | 0.72 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2584526 | 0.72 | OPRL1 (0.40) | OPRL1 | |
| SCHEMBL8121937 | 0.71 | OPRM1 (0.47) | OPRM1OPRL1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14947625 | 0.70 | OPRM1 (0.40) | OPRM1OPRL1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022094668-A1 | PROCESS FOR PREPARING HETEROCYCLIC METHANONE COMPOUNDS AND AZA-BICYCLO INTERMEDIATES THEREOF | Actinogen Medical Limited (AU) | 2022-05-12 | — | — | WO | disclosed |
| US-9834549-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]OCT-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834549-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]OCT-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20160251346-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160251346-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-09-01 | — | — | US | disclosed |
| US-9365564-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-14 | — | — | US | disclosed |
| US-9365564-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-14 | — | — | US | disclosed |
| US-20130123268-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2013-05-16 | — | — | US | disclosed |
| US-20130123268-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2013-05-16 | — | — | US | disclosed |
| US-7459556-B2 | Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols | SCHERING-PLOUGH LTD. (CH) | 2008-12-02 | — | — | US | disclosed |
| US-7459556-B2 | Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols | SCHERING-PLOUGH LTD. (CH) | 2008-12-02 | — | — | US | disclosed |
| US-7459556-B2 | Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols | SCHERING-PLOUGH LTD. (CH) | 2008-12-02 | — | — | US | disclosed |
| EP-1791838-A2 | PROCESS FOR PREPARING SUBSTITUTED 8-AZABICYCLO[3.2.1] OCTAN-3-OLS | Schering-Plough Ltd. (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006031788-A2 | PROCESS FOR PREPARING SUBSTITUTED 8-AZABICYCLO[3.2.1] OCTAN-3-OLS | SCHERING-PLOUGH LTD. (CH) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058343-A1 | Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols | SCHERING-PLOUGH LTD. (CH) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251346-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | HSD11B1, HSD3B1, HSD17B1 | OPRM1 2559/4885OPRL1 3182/4885CHRNB2 1319/4885 |
| US-20130123268-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | HSD11B1, HSD3B1, HSD17B1 | OPRM1 2559/4885OPRL1 3182/4885CHRNB2 1319/4885 |
| US-20060058343-A1 | Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols | ODC1, CYP2C8, OR10J3 | OPRM1 223/4885OPRL1 632/4885CHRNB2 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.